.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, people along with metastatic stomach cysts that received biomarker-matched treatments based upon distributing lump DNA profiling showed a more significant clinical perk than those acquiring unequaled therapy.